Full Press Release Details
Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE setmelanotide for Patients with Bardet Biedl Syndro.
RYTM
Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE setmelanotide for Patients with Bardet Biedl Syndro
Key Takeaway: Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE setmelanotide for Patients with Bardet Biedl Syndro